Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
GIP/GLP-1 dual agonists such as tirzepatide additionally engage the GIP receptor, layering in a second incretin mechanism
Patients begin with a clinically appropriate starting dose and increase gradually based on individual tolerance and metabolic response, a strategy proven safer than fixed-dose protocols
There are no shortcuts here
The most commonly encountered imbalances include: Hyponatraemia (low sodium) can develop when fluid intake exceeds sodium intake or when significant sodium is lost through vomiting or diarrhoea
Start the complete protocol
doi:10.1097/GME.0b013e3181806446
US$ 25.51
US$ 27.15
US$ 20.77
US$ 25.05
US$ 25.46
US$ 27.77
